Alloplex has developed a differentiated, non-engineered, autologous cellular therapy derived from peripheral blood mononuclear cells that undergo a proprietary activation process.

The resulting SUPLEXA therapeutic cells display broad anti-tumor activity and are comprised of cells of both innate and adaptive phenotypes.

The inaugural single-agent SUPLEXA survey study in advanced solid cancer patients has successfully met all pre-specified endpoints.

With an impeccable safety profile, Alloplex has identified SUPLEXA-responsive tumor types setting it apart from other cell therapies.

Series A

Total: USD $26M Raised

SUPLEXA-101: Phase 1 40-patient survey study phase 1 solid tumor study in Australia. Enrollment closed Feb 2024. Single-agent responses of high durability.

Upcoming studies will leverage the highly favourable safety profile and add SUPLEXA to standard-of-care treatments.

Cell therapies

Oncology - Solid Tumor